196 related articles for article (PubMed ID: 30150483)
1. A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
Garrett KL; Chen J; Maas BM; Cottrell ML; Prince HA; Sykes C; Schauer AP; White N; Dumond JB
J Pharmacol Exp Ther; 2018 Nov; 367(2):245-251. PubMed ID: 30150483
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
Okochi H; Louie A; Phung N; Zhang K; Tallerico RM; Kuncze K; Spinelli MA; Koss CA; Benet LZ; Gandhi M
Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745
[TBL] [Abstract][Full Text] [Related]
3. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288
[TBL] [Abstract][Full Text] [Related]
4. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
Robles G; Sauermilch D; Gandhi M; Starks TJ
AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
[TBL] [Abstract][Full Text] [Related]
5. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
[TBL] [Abstract][Full Text] [Related]
7. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
D'Angelo AB; Westmoreland DA; Carneiro PB; Johnson J; Grov C
AIDS Patient Care STDS; 2021 Aug; 35(8):327-334. PubMed ID: 34375141
[TBL] [Abstract][Full Text] [Related]
8. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
[TBL] [Abstract][Full Text] [Related]
9. Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
Herrera C; Serwanga J; Else L; Limakatso L; Opoka D; Ssemata AS; Pillay AD; Namubiru P; Seiphetlo TB; Odoch G; Mugaba S; Seatlholo P; Alieu A; Penchala SD; Muhumuza R; Alinde B; Petkov S; O'Hagan K; Callebaut C; Seeley J; Weiss H; Khoo S; Chiodi F; Gray CM; Kaleebu P; Webb EL; Martinson N; Fox J;
EBioMedicine; 2023 Jul; 93():104648. PubMed ID: 37327677
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
[TBL] [Abstract][Full Text] [Related]
11. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
13. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
Plosker GL
Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
[TBL] [Abstract][Full Text] [Related]
14. A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.
Cottrell ML; Yang KH; Prince HM; Sykes C; White N; Malone S; Dellon ES; Madanick RD; Shaheen NJ; Hudgens MG; Wulff J; Patterson KB; Nelson JA; Kashuba AD
J Infect Dis; 2016 Jul; 214(1):55-64. PubMed ID: 26917574
[TBL] [Abstract][Full Text] [Related]
15. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis.
Massih SA; Atta MG; Thio CL; Tornheim JA; Fuchs EJ; Bakshi RP; Marzinke MA; Hendrix CW; Weld ED
AIDS Res Ther; 2024 May; 21(1):34. PubMed ID: 38773606
[TBL] [Abstract][Full Text] [Related]
17. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
Hendrix CW; Andrade A; Bumpus NN; Kashuba AD; Marzinke MA; Moore A; Anderson PL; Bushman LR; Fuchs EJ; Wiggins I; Radebaugh C; Prince HA; Bakshi RP; Wang R; Richardson P; Shieh E; McKinstry L; Li X; Donnell D; Elharrar V; Mayer KH; Patterson KB
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):32-43. PubMed ID: 26414912
[TBL] [Abstract][Full Text] [Related]
18. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
Seifert SM; Glidden DV; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Rower C; Klein B; Kerr BJ; Guida LA; Zheng JH; Bushman LR; Anderson PL
Clin Infect Dis; 2015 Mar; 60(5):804-10. PubMed ID: 25409469
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
20. Emtricitabine/tenofovir alafenamide usage in a Scottish sexual health service providing HIV pre-exposure prophylaxis: A service evaluation.
Burley N; MacDonald R; Khan A
Int J STD AIDS; 2024 Mar; 35(4):308-310. PubMed ID: 38053307
[No Abstract] [Full Text] [Related]
[Next] [New Search]
